The Diagnosis: Blaschkoid Graft-vs-host Disease

The patient had a history of myelodysplastic syndrome and underwent a bone marrow transplant 1 year prior to presentation. She had acute graft-vs-host disease (GVHD) 6 weeks following the transplant, which resolved with high-dose prednisone followed by UVB phototherapy. Skin biopsy demonstrated lichenoid dermatitis with vacuolar degeneration, dyskeratosis, and prominent pigment incontinence (Figure). Based on these findings and her clinical presentation, a diagnosis of blaschkoid GVHD was made.

Although acute GVHD is the result of immunocompetent donor T cells recognizing host tissues as foreign and initiating an immune response, the pathophysiology of chronic GVHD is not well understood.^1,2 Theories for disease pathogenesis in chronic GVHD suggest an underlying autoimmune and/or alloreactive process.^2-5 The skin often is the first organ affected in acute GVHD, and patients generally present with a pruritic morbilliform eruption that begins on the trunk and spreads to the rest of the body.^1,2 Cutaneous manifestations of chronic GVHD may be protean. Lesions can resemble systemic sclerosis or morphea, lichen planus, psoriasis, ichthyosis, and many other conditions.²

The differential diagnosis of linear dermatoses includes herpes zoster, contact dermatitis, lichen striatus (blaschkitis), nevus unius lateris, inflammatory linear verrucous epidermal nevus, and incontinentia pigmenti.^6,7 Lichen planus-like chronic GVHD occurring in a linear distribution has been described.^6-14 Distinction between dermatomal and blaschkoid processes is diagnostically important. In the case of GVHD, dermatomal distribution may suggest an association between GVHD and prior herpes simplex virus or varicella-zoster virus infection.^6,8 Herpesvirus may alter surface antigens of keratinocytes, rendering them targets of donor lymphocytes, and antibodies to viral particles may cross-react with host keratinocyte HLA antigens. It also is possible that dermatomal GVHD may simply be a type of isomorphic response (Köbner phenomenon).⁸

When cutaneous GVHD follows Blaschko lines, other mechanisms appear to be at play.^9-14 It is plausible that these patients have an underlying genetic mosaicism, perhaps the result of a postzygotic mutation, that results in a daughter cell population that expresses surface antigens different from those of the primary cell population found elsewhere in the skin. Donor lymphocytes may selectively react to this mosaic population, leading to the clinical picture of chronic GVHD oriented along Blaschko lines.^10,11,13,14 

In conclusion, lichenoid linear GVHD following Blaschko lines is an uncommon presentation of chronic GVHD that highlights the heterogeneity of this disease and should be considered in the appropriate clinical setting.

The Diagnosis: Blaschkoid Graft-vs-host Disease

The patient had a history of myelodysplastic syndrome and underwent a bone marrow transplant 1 year prior to presentation. She had acute graft-vs-host disease (GVHD) 6 weeks following the transplant, which resolved with high-dose prednisone followed by UVB phototherapy. Skin biopsy demonstrated lichenoid dermatitis with vacuolar degeneration, dyskeratosis, and prominent pigment incontinence (Figure). Based on these findings and her clinical presentation, a diagnosis of blaschkoid GVHD was made.

Although acute GVHD is the result of immunocompetent donor T cells recognizing host tissues as foreign and initiating an immune response, the pathophysiology of chronic GVHD is not well understood.^1,2 Theories for disease pathogenesis in chronic GVHD suggest an underlying autoimmune and/or alloreactive process.^2-5 The skin often is the first organ affected in acute GVHD, and patients generally present with a pruritic morbilliform eruption that begins on the trunk and spreads to the rest of the body.^1,2 Cutaneous manifestations of chronic GVHD may be protean. Lesions can resemble systemic sclerosis or morphea, lichen planus, psoriasis, ichthyosis, and many other conditions.²

The differential diagnosis of linear dermatoses includes herpes zoster, contact dermatitis, lichen striatus (blaschkitis), nevus unius lateris, inflammatory linear verrucous epidermal nevus, and incontinentia pigmenti.^6,7 Lichen planus-like chronic GVHD occurring in a linear distribution has been described.^6-14 Distinction between dermatomal and blaschkoid processes is diagnostically important. In the case of GVHD, dermatomal distribution may suggest an association between GVHD and prior herpes simplex virus or varicella-zoster virus infection.^6,8 Herpesvirus may alter surface antigens of keratinocytes, rendering them targets of donor lymphocytes, and antibodies to viral particles may cross-react with host keratinocyte HLA antigens. It also is possible that dermatomal GVHD may simply be a type of isomorphic response (Köbner phenomenon).⁸

When cutaneous GVHD follows Blaschko lines, other mechanisms appear to be at play.^9-14 It is plausible that these patients have an underlying genetic mosaicism, perhaps the result of a postzygotic mutation, that results in a daughter cell population that expresses surface antigens different from those of the primary cell population found elsewhere in the skin. Donor lymphocytes may selectively react to this mosaic population, leading to the clinical picture of chronic GVHD oriented along Blaschko lines.^10,11,13,14 

In conclusion, lichenoid linear GVHD following Blaschko lines is an uncommon presentation of chronic GVHD that highlights the heterogeneity of this disease and should be considered in the appropriate clinical setting.

The Diagnosis: Blaschkoid Graft-vs-host Disease

The patient had a history of myelodysplastic syndrome and underwent a bone marrow transplant 1 year prior to presentation. She had acute graft-vs-host disease (GVHD) 6 weeks following the transplant, which resolved with high-dose prednisone followed by UVB phototherapy. Skin biopsy demonstrated lichenoid dermatitis with vacuolar degeneration, dyskeratosis, and prominent pigment incontinence (Figure). Based on these findings and her clinical presentation, a diagnosis of blaschkoid GVHD was made.

Although acute GVHD is the result of immunocompetent donor T cells recognizing host tissues as foreign and initiating an immune response, the pathophysiology of chronic GVHD is not well understood.^1,2 Theories for disease pathogenesis in chronic GVHD suggest an underlying autoimmune and/or alloreactive process.^2-5 The skin often is the first organ affected in acute GVHD, and patients generally present with a pruritic morbilliform eruption that begins on the trunk and spreads to the rest of the body.^1,2 Cutaneous manifestations of chronic GVHD may be protean. Lesions can resemble systemic sclerosis or morphea, lichen planus, psoriasis, ichthyosis, and many other conditions.²

The differential diagnosis of linear dermatoses includes herpes zoster, contact dermatitis, lichen striatus (blaschkitis), nevus unius lateris, inflammatory linear verrucous epidermal nevus, and incontinentia pigmenti.^6,7 Lichen planus-like chronic GVHD occurring in a linear distribution has been described.^6-14 Distinction between dermatomal and blaschkoid processes is diagnostically important. In the case of GVHD, dermatomal distribution may suggest an association between GVHD and prior herpes simplex virus or varicella-zoster virus infection.^6,8 Herpesvirus may alter surface antigens of keratinocytes, rendering them targets of donor lymphocytes, and antibodies to viral particles may cross-react with host keratinocyte HLA antigens. It also is possible that dermatomal GVHD may simply be a type of isomorphic response (Köbner phenomenon).⁸

When cutaneous GVHD follows Blaschko lines, other mechanisms appear to be at play.^9-14 It is plausible that these patients have an underlying genetic mosaicism, perhaps the result of a postzygotic mutation, that results in a daughter cell population that expresses surface antigens different from those of the primary cell population found elsewhere in the skin. Donor lymphocytes may selectively react to this mosaic population, leading to the clinical picture of chronic GVHD oriented along Blaschko lines.^10,11,13,14 

In conclusion, lichenoid linear GVHD following Blaschko lines is an uncommon presentation of chronic GVHD that highlights the heterogeneity of this disease and should be considered in the appropriate clinical setting.

The Diagnosis: Chronic Hyperplastic Candidiasis (Nodular Form)

Chronic hyperplastic candidiasis (CHC) is a rare form of oropharyngeal candidiasis. The most frequent clinical presentation is a white plaque that cannot be detached (also known as candidal leukoplakia). It usually involves the anterior buccal mucosa, mainly the commissural area, though the palate and tongue also can be affected. The nodular type of CHC is even less common. Our patient exhibited the typical clinical presentation of the nodular type of CHC.^1-3 The differential diagnosis includes leukoplakia, premalignant and malignant epithelial lesions, granular cell tumor, and florid oral papillomatosis.^1,3 A biopsy usually is required for diagnostic confirmation. Histologically, CHC is characterized by parakeratosis and a hyperplastic epithelium invaded by Candida hyphae.⁴ Because Candida species are commensal in up to 50% of the healthy population, superficial colonization of tissues is not enough to indicate notable disease.¹ In our patient, the histopathology revealed a hyperplastic mucosa without atypia and numerous hyphae (Figure). Both lingual swab and tissue cultures revealed high growth of Candida albicans. 

Infection by C albicans depends on pathogen virulence and host factors such as wearing dentures, reduced salivary production, smoking habit, or immunosuppression.^1,4 Apart from wearing dentures, our patient did not present with other predisposing factors. It is possible that the immunosuppressive status related to old age and associated oral changes contributed to Candida infection in this case. 

Topical or systemic antifungal agents together with the elimination of predisposing factors are usual first-line treatments. Because of the relationship with atypia and the possibility of evolving into carcinoma in untreated or persistent lesions, follow-up is necessary to verify complete resolution after treatment.^1,3,4 In the case reported herein, the lesions disappeared after 15 days of oral fluconazole treatment.

The Diagnosis: Chronic Hyperplastic Candidiasis (Nodular Form)

Chronic hyperplastic candidiasis (CHC) is a rare form of oropharyngeal candidiasis. The most frequent clinical presentation is a white plaque that cannot be detached (also known as candidal leukoplakia). It usually involves the anterior buccal mucosa, mainly the commissural area, though the palate and tongue also can be affected. The nodular type of CHC is even less common. Our patient exhibited the typical clinical presentation of the nodular type of CHC.^1-3 The differential diagnosis includes leukoplakia, premalignant and malignant epithelial lesions, granular cell tumor, and florid oral papillomatosis.^1,3 A biopsy usually is required for diagnostic confirmation. Histologically, CHC is characterized by parakeratosis and a hyperplastic epithelium invaded by Candida hyphae.⁴ Because Candida species are commensal in up to 50% of the healthy population, superficial colonization of tissues is not enough to indicate notable disease.¹ In our patient, the histopathology revealed a hyperplastic mucosa without atypia and numerous hyphae (Figure). Both lingual swab and tissue cultures revealed high growth of Candida albicans. 

Infection by C albicans depends on pathogen virulence and host factors such as wearing dentures, reduced salivary production, smoking habit, or immunosuppression.^1,4 Apart from wearing dentures, our patient did not present with other predisposing factors. It is possible that the immunosuppressive status related to old age and associated oral changes contributed to Candida infection in this case. 

Topical or systemic antifungal agents together with the elimination of predisposing factors are usual first-line treatments. Because of the relationship with atypia and the possibility of evolving into carcinoma in untreated or persistent lesions, follow-up is necessary to verify complete resolution after treatment.^1,3,4 In the case reported herein, the lesions disappeared after 15 days of oral fluconazole treatment.

The Diagnosis: Chronic Hyperplastic Candidiasis (Nodular Form)

Chronic hyperplastic candidiasis (CHC) is a rare form of oropharyngeal candidiasis. The most frequent clinical presentation is a white plaque that cannot be detached (also known as candidal leukoplakia). It usually involves the anterior buccal mucosa, mainly the commissural area, though the palate and tongue also can be affected. The nodular type of CHC is even less common. Our patient exhibited the typical clinical presentation of the nodular type of CHC.^1-3 The differential diagnosis includes leukoplakia, premalignant and malignant epithelial lesions, granular cell tumor, and florid oral papillomatosis.^1,3 A biopsy usually is required for diagnostic confirmation. Histologically, CHC is characterized by parakeratosis and a hyperplastic epithelium invaded by Candida hyphae.⁴ Because Candida species are commensal in up to 50% of the healthy population, superficial colonization of tissues is not enough to indicate notable disease.¹ In our patient, the histopathology revealed a hyperplastic mucosa without atypia and numerous hyphae (Figure). Both lingual swab and tissue cultures revealed high growth of Candida albicans. 

Infection by C albicans depends on pathogen virulence and host factors such as wearing dentures, reduced salivary production, smoking habit, or immunosuppression.^1,4 Apart from wearing dentures, our patient did not present with other predisposing factors. It is possible that the immunosuppressive status related to old age and associated oral changes contributed to Candida infection in this case. 

Topical or systemic antifungal agents together with the elimination of predisposing factors are usual first-line treatments. Because of the relationship with atypia and the possibility of evolving into carcinoma in untreated or persistent lesions, follow-up is necessary to verify complete resolution after treatment.^1,3,4 In the case reported herein, the lesions disappeared after 15 days of oral fluconazole treatment.

SAN ANTONIO – Most women with hormone receptor–positive breast cancer treated with an aromatase inhibitor will eventually develop resistance to these agents. Strategies for overcoming resistance include the addition of everolimus (Affinitor) to a steroidal aromatase inhibitor (AI) such as exemestane (Aromasin), as in the BOLERO-2 trial.

Alternatively, blocking estrogen-receptor signaling through the use of a selective estrogen receptor down regulator, such as fulvestrant (Faslodex), may result in more complete blockade of the ER signaling pathway than would a steroidal AI such as exemestane.

In this video interview at the San Antonio Breast Cancer Symposium, Noah S. Kornblum, MD, of the Montefiore-Einstein Center for Cancer Care, New York, discusses findings from the phase II PrECOG 0102 trial comparing a combination of fulvestrant and everolimus to fulvestrant and placebo for the treatment of postmenopausal women with hormone receptor–positive, HER2-negative breast cancer resistant to AI therapy.

The combination was associated with a median progression-free survival of 10.4 months, compared with 5.1 months for fulvestrant plus placebo (hazard ratio, 0.60; P = .02).

Dr. Kornblum says that the study provides additional evidence for adding everolimus to anti-estrogen therapy in AI-resistant disease.

SAN ANTONIO – Most women with hormone receptor–positive breast cancer treated with an aromatase inhibitor will eventually develop resistance to these agents. Strategies for overcoming resistance include the addition of everolimus (Affinitor) to a steroidal aromatase inhibitor (AI) such as exemestane (Aromasin), as in the BOLERO-2 trial.

Alternatively, blocking estrogen-receptor signaling through the use of a selective estrogen receptor down regulator, such as fulvestrant (Faslodex), may result in more complete blockade of the ER signaling pathway than would a steroidal AI such as exemestane.

In this video interview at the San Antonio Breast Cancer Symposium, Noah S. Kornblum, MD, of the Montefiore-Einstein Center for Cancer Care, New York, discusses findings from the phase II PrECOG 0102 trial comparing a combination of fulvestrant and everolimus to fulvestrant and placebo for the treatment of postmenopausal women with hormone receptor–positive, HER2-negative breast cancer resistant to AI therapy.

The combination was associated with a median progression-free survival of 10.4 months, compared with 5.1 months for fulvestrant plus placebo (hazard ratio, 0.60; P = .02).

Dr. Kornblum says that the study provides additional evidence for adding everolimus to anti-estrogen therapy in AI-resistant disease.

SAN ANTONIO – Most women with hormone receptor–positive breast cancer treated with an aromatase inhibitor will eventually develop resistance to these agents. Strategies for overcoming resistance include the addition of everolimus (Affinitor) to a steroidal aromatase inhibitor (AI) such as exemestane (Aromasin), as in the BOLERO-2 trial.

Alternatively, blocking estrogen-receptor signaling through the use of a selective estrogen receptor down regulator, such as fulvestrant (Faslodex), may result in more complete blockade of the ER signaling pathway than would a steroidal AI such as exemestane.

In this video interview at the San Antonio Breast Cancer Symposium, Noah S. Kornblum, MD, of the Montefiore-Einstein Center for Cancer Care, New York, discusses findings from the phase II PrECOG 0102 trial comparing a combination of fulvestrant and everolimus to fulvestrant and placebo for the treatment of postmenopausal women with hormone receptor–positive, HER2-negative breast cancer resistant to AI therapy.

The combination was associated with a median progression-free survival of 10.4 months, compared with 5.1 months for fulvestrant plus placebo (hazard ratio, 0.60; P = .02).

Dr. Kornblum says that the study provides additional evidence for adding everolimus to anti-estrogen therapy in AI-resistant disease.

Between 700,000 and 1 million people fall each year in U.S. hospitals, and about a third of those result in injuries that add an additional 6.3 days to hospital stays, according to a report from the Joint Commission Center for Transforming Healthcare. Some 11,000 falls are fatal. The Joint Commission Center for Transforming Healthcare has now issued a report on the subject called “Preventing Patient Falls: A Systematic Approach from the Joint Commission Center for Transforming Healthcare Project.”1

“We try to pick those topics that healthcare organizations just haven’t been able to fully tackle even though they’ve put a lot of time and resources into trying to fix them,” says Kelly Barnes, MS, a center project lead in the Center for Transforming Healthcare at The Joint Commission.

The Joint Commission project involved seven hospitals that used Robust Process Improvement, which incorporates tools from Lean Six Sigma and change management methodologies, to reduce falls with injury on inpatient pilot units within their organizations.

During the project, each organization identified the specific factors that led to falls with injury in their environment and developed solutions targeted to those factors. The organizations identified 30 root causes and developed 21 targeted solutions. Because the contributing factors were different at each organization, solution sets were unique to each. Afterward, the organizations saw an aggregate 35% reduction in falls and a 62% reduction in falls with injury.

“One of the takeaways is that you really need support across an organization to have success,” Barnes says. “The more engaged the entire organization is from top down all the way to the bottom, the more successful people are in solving the problems.”

The study resulted in a Targeted Solutions Tool (TST), free to all Joint Commission–accredited customers, to help hospitals.

“You can put your data right into the tool,” Barnes says. “It tells you what your top contributing factors are, and it gives you the solutions that have worked for those contributing factors at other organizations.”

Reference

Health Research & Educational Trust. Preventing patient falls: a systematic approach from the Joint Commission Center for Transforming Healthcare project. Hospitals in Pursuit of Excellence website.

Between 700,000 and 1 million people fall each year in U.S. hospitals, and about a third of those result in injuries that add an additional 6.3 days to hospital stays, according to a report from the Joint Commission Center for Transforming Healthcare. Some 11,000 falls are fatal. The Joint Commission Center for Transforming Healthcare has now issued a report on the subject called “Preventing Patient Falls: A Systematic Approach from the Joint Commission Center for Transforming Healthcare Project.”1

“We try to pick those topics that healthcare organizations just haven’t been able to fully tackle even though they’ve put a lot of time and resources into trying to fix them,” says Kelly Barnes, MS, a center project lead in the Center for Transforming Healthcare at The Joint Commission.

The Joint Commission project involved seven hospitals that used Robust Process Improvement, which incorporates tools from Lean Six Sigma and change management methodologies, to reduce falls with injury on inpatient pilot units within their organizations.

During the project, each organization identified the specific factors that led to falls with injury in their environment and developed solutions targeted to those factors. The organizations identified 30 root causes and developed 21 targeted solutions. Because the contributing factors were different at each organization, solution sets were unique to each. Afterward, the organizations saw an aggregate 35% reduction in falls and a 62% reduction in falls with injury.

“One of the takeaways is that you really need support across an organization to have success,” Barnes says. “The more engaged the entire organization is from top down all the way to the bottom, the more successful people are in solving the problems.”

The study resulted in a Targeted Solutions Tool (TST), free to all Joint Commission–accredited customers, to help hospitals.

“You can put your data right into the tool,” Barnes says. “It tells you what your top contributing factors are, and it gives you the solutions that have worked for those contributing factors at other organizations.”

Reference

Health Research & Educational Trust. Preventing patient falls: a systematic approach from the Joint Commission Center for Transforming Healthcare project. Hospitals in Pursuit of Excellence website.

Between 700,000 and 1 million people fall each year in U.S. hospitals, and about a third of those result in injuries that add an additional 6.3 days to hospital stays, according to a report from the Joint Commission Center for Transforming Healthcare. Some 11,000 falls are fatal. The Joint Commission Center for Transforming Healthcare has now issued a report on the subject called “Preventing Patient Falls: A Systematic Approach from the Joint Commission Center for Transforming Healthcare Project.”1

“We try to pick those topics that healthcare organizations just haven’t been able to fully tackle even though they’ve put a lot of time and resources into trying to fix them,” says Kelly Barnes, MS, a center project lead in the Center for Transforming Healthcare at The Joint Commission.

The Joint Commission project involved seven hospitals that used Robust Process Improvement, which incorporates tools from Lean Six Sigma and change management methodologies, to reduce falls with injury on inpatient pilot units within their organizations.

During the project, each organization identified the specific factors that led to falls with injury in their environment and developed solutions targeted to those factors. The organizations identified 30 root causes and developed 21 targeted solutions. Because the contributing factors were different at each organization, solution sets were unique to each. Afterward, the organizations saw an aggregate 35% reduction in falls and a 62% reduction in falls with injury.

“One of the takeaways is that you really need support across an organization to have success,” Barnes says. “The more engaged the entire organization is from top down all the way to the bottom, the more successful people are in solving the problems.”

The study resulted in a Targeted Solutions Tool (TST), free to all Joint Commission–accredited customers, to help hospitals.

“You can put your data right into the tool,” Barnes says. “It tells you what your top contributing factors are, and it gives you the solutions that have worked for those contributing factors at other organizations.”

Reference

Health Research & Educational Trust. Preventing patient falls: a systematic approach from the Joint Commission Center for Transforming Healthcare project. Hospitals in Pursuit of Excellence website.

Inpatient hospitalization can be a key time for patients to quit smoking, according to an abstract called “No More Butts: An Automated System for Inpatient Smoking Cessation Team Consults.”1

“Tobacco smoking continues to be one of the most important public health threats that we face,” says lead author Sujatha Sankaran, MD, assistant clinical professor in the division of hospital medicine and medical director of smoking cessation at the University of California, San Francisco. “Hospitalization is an extremely important moment and provides an excellent opportunity to counsel and provide cessation resources for people who are concerned about their health.”

Inpatients who receive smoking cessation counseling, nicotine replacement, and referral to outpatient resources have increased quit rates six weeks after hospital discharge, their research showed.

However, according to the abstract, in 2014:

• 34.5% of tobacco users admitted to one 600-bed academic hospital were documented as having received and accepted tobacco cessation counseling
• 45.7% of tobacco users received nicotine replacement therapy
• 1.35% of tobacco users received after-discharge consultations to outpatient smoking cessation resources

Researchers piloted a system in which a dedicated respiratory therapist–staffed smoking cessation consult service was trained to provide targeted tobacco cessation services to all inpatients who use tobacco. Of 1944 patients identified as using tobacco, 1545 received and accepted cessation counseling from a trained member of the Smoking Cessation Team, 1526 received nicotine replacement therapy, and 464 received an electronic referral to either a telephone or in-person quit line

“Hospitalists know firsthand the serious harm that tobacco use causes to patients but often are overwhelmed by the acute issues of patients and are unable to fully address tobacco use with hospitalized patients,” Dr. Sankaran says. “An automated cessation service can help lessen this burden by providing automatic cessation resources to all tobacco users.”

Reference

1. Sankaran S, Burke R, O’Keefe S. No more butts: an automated system for inpatient smoking cessation team consults [abstract]. J Hosp Med. 2016;11(suppl 1). Accessed November 9, 2016.

Inpatient hospitalization can be a key time for patients to quit smoking, according to an abstract called “No More Butts: An Automated System for Inpatient Smoking Cessation Team Consults.”1

“Tobacco smoking continues to be one of the most important public health threats that we face,” says lead author Sujatha Sankaran, MD, assistant clinical professor in the division of hospital medicine and medical director of smoking cessation at the University of California, San Francisco. “Hospitalization is an extremely important moment and provides an excellent opportunity to counsel and provide cessation resources for people who are concerned about their health.”

Inpatients who receive smoking cessation counseling, nicotine replacement, and referral to outpatient resources have increased quit rates six weeks after hospital discharge, their research showed.

However, according to the abstract, in 2014:

• 34.5% of tobacco users admitted to one 600-bed academic hospital were documented as having received and accepted tobacco cessation counseling
• 45.7% of tobacco users received nicotine replacement therapy
• 1.35% of tobacco users received after-discharge consultations to outpatient smoking cessation resources

Researchers piloted a system in which a dedicated respiratory therapist–staffed smoking cessation consult service was trained to provide targeted tobacco cessation services to all inpatients who use tobacco. Of 1944 patients identified as using tobacco, 1545 received and accepted cessation counseling from a trained member of the Smoking Cessation Team, 1526 received nicotine replacement therapy, and 464 received an electronic referral to either a telephone or in-person quit line

“Hospitalists know firsthand the serious harm that tobacco use causes to patients but often are overwhelmed by the acute issues of patients and are unable to fully address tobacco use with hospitalized patients,” Dr. Sankaran says. “An automated cessation service can help lessen this burden by providing automatic cessation resources to all tobacco users.”

Reference

1. Sankaran S, Burke R, O’Keefe S. No more butts: an automated system for inpatient smoking cessation team consults [abstract]. J Hosp Med. 2016;11(suppl 1). Accessed November 9, 2016.

Inpatient hospitalization can be a key time for patients to quit smoking, according to an abstract called “No More Butts: An Automated System for Inpatient Smoking Cessation Team Consults.”1

“Tobacco smoking continues to be one of the most important public health threats that we face,” says lead author Sujatha Sankaran, MD, assistant clinical professor in the division of hospital medicine and medical director of smoking cessation at the University of California, San Francisco. “Hospitalization is an extremely important moment and provides an excellent opportunity to counsel and provide cessation resources for people who are concerned about their health.”

Inpatients who receive smoking cessation counseling, nicotine replacement, and referral to outpatient resources have increased quit rates six weeks after hospital discharge, their research showed.

However, according to the abstract, in 2014:

• 34.5% of tobacco users admitted to one 600-bed academic hospital were documented as having received and accepted tobacco cessation counseling
• 45.7% of tobacco users received nicotine replacement therapy
• 1.35% of tobacco users received after-discharge consultations to outpatient smoking cessation resources

Researchers piloted a system in which a dedicated respiratory therapist–staffed smoking cessation consult service was trained to provide targeted tobacco cessation services to all inpatients who use tobacco. Of 1944 patients identified as using tobacco, 1545 received and accepted cessation counseling from a trained member of the Smoking Cessation Team, 1526 received nicotine replacement therapy, and 464 received an electronic referral to either a telephone or in-person quit line

“Hospitalists know firsthand the serious harm that tobacco use causes to patients but often are overwhelmed by the acute issues of patients and are unable to fully address tobacco use with hospitalized patients,” Dr. Sankaran says. “An automated cessation service can help lessen this burden by providing automatic cessation resources to all tobacco users.”

Reference

1. Sankaran S, Burke R, O’Keefe S. No more butts: an automated system for inpatient smoking cessation team consults [abstract]. J Hosp Med. 2016;11(suppl 1). Accessed November 9, 2016.

A pressure ulcer (PrU) is a localized injury to the skin and/or deep tissues that is due to pressure, friction, or shearing forces. Pressure ulcers are strongly associated with serious comorbidities, particularly inadequate nutrition and immobility.^1,2 Pressure ulcers increase hospital costs significantly. In the U.S., PrU care is about $11 billion annually and a cost of between $2,000 and $21,410 per individual PrU.^3-5

The impact of nosocomial PrUs remains a key health and economic concern of acute care facilities worldwide. In the U.S., about 2.5 million inpatients annually develop some degree of a PrU during their hospital stay. The reported incidence rates range from 0.4% to 38%.^3,6 Each year about 60,000 people die of complications of a PrU.^3,6,7 Inadequate nutrition is a critical factor that contributes to the incidence of PrUs.^8-12 Consequences of inadequate nutrition have included alterations in skin integrity resulting in PrUs, longer hospital stays, increased costs of care, and higher rates of mortality.⁹ As a patient’s nutritional status becomes compromised, the likelihood of developing a PrU increases, especially if an individual is immobilized.^7,9-11,13

Braden Scale History

The Braden Scale for Predicting Pressure Sore Risk was developed by Barbara Braden, PhD, RN, and Nancy Bergstrom, PhD, RN, in 1987.^14,15 Originally established for use in long-term care facilities, the scale is recommended by the National Pressure Ulcer Advisory Panel in its clinical practice guidelines and is the most frequently used risk assessment tool by nurses in acute care facilities worldwide.¹

The scale is composed of 6 factors: sensory perception, moisture, activity, mobility, friction and shear, and nutrition.¹⁴ Each factor is scored on a scale of 1 to 4 points (friction and shear are scored on a point scale of only 1 to 3) for a total possible score of 6 to 23 points (the lower the score, the greater the assumed PrU risk).

The Braden nutrition subscale relies heavily on recording observed or patient self-reported eating habits. It is typically documented by nurses who assess the daily intake of meals: recording a score of 4 if the patient’s meal intake is excellent (eats most of every meal), 3 if the patient’s intake is adequate (eats more than half of most meals), 2 if the patient’s intake is probably inadequate (rarely eats a complete meal), and 1 if a patient’s intake is very poor (never eats a complete meal) (Table 1).¹⁴

Historically, the Braden scale is reported to have good reliability when used by registered nurses as a risk prediction tool.^14,16 A recent review also reported high interrater reliability of the Braden scale total score among nurses, nursing assistants, and graduate assistants.¹⁷ However, other studies suggest certain subscales (such as sensory and nutrition) may have very low interrater reliability among nurses and poor PrU predictability.^18,19 To date, there are no known studies evaluating the agreement of the Braden nutrition subscale primarily used by nurses and the VA Nutrition Classification Scheme (VANCS) used by dietitians.

The VA standard of care recommends that PrU risk assessments are documented for all hospitalized veterans within 24 hours of admission, daily, with transfers or discharges, and when there is a status change in the patient. In addition, nutritional assessments by dietitians (using the VANCS) are encouraged within 24 hours of acute care hospitalization.²⁰

The VANCS performed by dietitians consists of 4 classifications: no nutritional compromise, mild nutritional compromise, moderate nutritional compromise, and severenutritional compromise. These classifications are based on well-documented “comprehensive approaches to defining nutritional status that uses multiple parameters” including nutrition history, weight (body mass index and weight loss), diagnoses, diet (and diet orders), brief physical assessment, and preliminary laboratory data (serum albumin/pre-albumin and total lymphocyte count).^20,21

The predictive ability of a risk assessment tool is critical to its clinical effectiveness in determining a clinical outcome.¹⁷ The Braden scale has been used for more than 30 years in various settings without any significant change to the scale or subscales. In a 2012 study, 4 medical factors were found to be more predictive of PrUs than the Braden scale total score in a sample of 213 acutely ill adult veterans.⁸ By performing a retrospective study using logistic regression predictive models, severe nutritional compromise (as identified by a dietitian), pneumonia, candidiasis, and surgery were identified as stronger predictors of PrU risk than was the Braden total score.⁸

With malnutrition as one of the most significant predictive factors in PrU risk, it is critical to determine whether discrepancies exist between the Braden nutrition subscale used primarily by nurses and the VANCS used by dietitians. Hence, the overall purpose of this study was to determine the level of agreement between the Braden nutrition subscale scores documented by nurses and the VANCS used by dietitians and examine the relationship of these assessments with PrU development.

Methods

The parent study was approved by the University of Florida Institutional Review Board before data collection. This secondary analysis of the parent study examined data already collected by Cowan and colleagues, which demonstrated the significance of nutritional compromise in PrU risk.⁸

The de-identified data subset consisted of general demographics, hospital length of stay, specific diagnoses, Braden scores, PrU status, and registered dietician nutritional classification data from 213 acutely ill veterans admitted to North Florida/South Georgia Veterans Health System (NF/SGVHS) in Florida for more than 3 days between January and July 2008.⁸ The sample consisted of 100 veterans with nosocomial PrUs and 113 veterans without PrUs during their admission.

Scoring

Using the de-identified dataset, the variables of interest (VANCS, Braden nutrition subscale score, and the presence/absence of PrU) were coded. The VANCS was given a corresponding score ranging from 1 to 4 (1, severe nutritional compromise; 2, moderate nutritional compromise; 3, mild nutritional compromise; and 4, no nutritional compromise). The Braden nutrition subscale ranged from 1 to 4 (1 very poor nutrition; 2, probably inadequate nutrition; 3, adequate nutrition; and 4, excellent nutrition). PrU development was coded as 0, no PrU development and 1, PrU development. All nutritional assessments had been recorded in the electronic health record before any PrU reported in the parent study.

Statistical Analysis

After coding the variables of interest, the data were transferred into SAS v 9.4 (Cary, NC). The data collected compared VANCS and Braden nutrition subscale results. In addition, the authors examined the agreement between the score assigned to the VANCS and Braden nutrition subscale results with a weighted κ analysis. Further, to determine the relationship between PrU and each of the nutrition assessment methods, chi-square or Fisher exact tests were conducted. The level of significance was set at .05.

Additionally, the authors computed sensitivity and specificity of the Braden nutrition subscale using the VANCS as the gold standard. The severe and moderately compromised categories of the VANCS combined to form the high-risk category, and the mild-to-no compromise categories were combined to form the low-risk category. The Braden nutrition subscale was similarly dichotomized with the very poor and probably inadequate intake forming the high-risk category and the adequate and excellent intake forming the low-risk category. Sensitivity and specificity of the Braden were then calculated.

Results

Nursing assessments using the Braden nutrition subscale were completed on 213 patients whose mean age (SD) was 71.0 (10.6) years. The VANCS documented by dietitians was completed on 205 patients. For 7 patients, a nutrition assessment was documented only by the Braden nutrition subscale and not the VANCS. Most of the patients were male (97%, n = 206), and white (81.4%, n = 171). The weighted κ statistic used to measure agreement between the Braden nutrition subscale and the VANCS was .17 (95% confidence interval = .07, .28).

Landis and colleagues suggest that a κ value of .17 may be interpreted as “fair” agreement.²² Figure 1 shows the agreement seen between the Braden nutrition subscale and VANCS. There was no strong agreement identified. Within each VANCS (severe compromise, moderate compromise, mild compromise, or no compromise), the numbers of patients rated as 1 (very poor intake), 2 (intake probably inadequate), or 3 (intake adequate) on the Braden nutrition subscale is given.

Figure 2 shows the percentage of patients who developed a PrU during hospitalization among different measures of Braden nutrition subscale vs VANCS. In Figure 2, nutritional categories 1, 2, and 3 correspond to very poor intake (Braden)/severe compromise (VANCS), probably inadequate intake (Braden)/moderate compromise (VANCS), and adequate intake (Braden)/mild compromise (VANCS), respectively. There were 3 patients who had a no compromise VANCS; none of these had a PrU, so their data are not represented in Figure 2.

​

Discussion

Findings from this study indicate that the VANCS documented by dietitians is superior in assessing nutritional risk and predicting the development of PrUs in acutely ill hospitalized veterans compared with the Braden nutrition subscale. This study also shows that the Braden nutrition subscale did not accurately predict PrU development in acutely ill veterans. This finding concurs with the Serpa and Santos study in which the Braden nutrition subscale scores were not predictive for PrU development in hospitalized patients.²³ They found that serum albumin levels and subjective global nutrition assessments were superior nutritional predictors of PrU development. These findings suggest modifications or enhancements are needed to address how nurses assess nutritional risk for PrUs in hospitalized patients.

One possible explanation for the findings in this study is that the nutrition subscale of the Braden tool asks the assessing clinician to evaluate the amount of food intake the patient is currently taking in for their usual meals. This assessment is highly subjective and speculative and does not account for recent intake fluctuations or weight loss. By comparison, the VANCS is more comprehensive in its ability to assess nutritional compromise based on multiple factors, such as recent weight loss, laboratory indices, body habitus, dentition, and swallowing ability.²⁰ The National Pressure Ulcer Advisory Panel suggests that following an acute care admission, a patient receive a consult from a dietitian if the health care provider suspects that the patient may be nutritionally compromised.¹ The study findings demonstrate the utility of the VANCS as predictive of PrU risk.

Unfortunately, the authors have learned that the VANCS may be phased out soon, and many VA facilities are no longer using it. Findings from this study and other recent scientific literature suggest that all inpatients may benefit from nutritional assessments by dietitians. When performed, dietitian assessments provide the basis for more accurate nursing assessment of nutritional risk and targeted interventions. Nursing professionals should be encouraged to review the dietitian assessment and consultation notes and to incorporate this information into a more comprehensive PrU prevention and treatment plan.

Interestingly, in spite of those assessed to have severe nutritional compromise by dietitian assessment (n = 39), very few of these patients (n = 4) had an ICD-9 diagnosis related to malnutrition (ICD-9 codes, 262, 273.8, 269.9, 263.9) entered in their chart for that hospitalization. This observation suggests that 88% of patients with severe nutritional compromise were not appropriately coded at discharge. Improper coding has implications for researchers using ICD-9 diagnosis codes at discharge for accurate analysis of risk factors as well as for health care providers who may look at coded diagnoses information in the charts when considering comorbid conditions for health management.

This study highlights the importance of nutritional status as a risk factor for PrU development. Reasons suggested for nutritional status seeming to be the most significant correlate to PrUs in the acute care setting include the following: decreased protein alters oncotic pressure, making tissue prone to edema; decreases in subcutaneous fat reduce protection from pressure effects; nutritional compromise alters cellular transport of nutrients and waste and makes tissue cells more vulnerable to deformation and physical stresses; and lactate (a by-product of anaerobic glycolysis) or any other metabolic by-product of malnutrition could cause biochemical stress, and tissue cells can die faster as a result of the increased plasma membrane permeability.^7,24-26

Limitations

This study was limited to 1 sample of veterans hospitalized in the 2 acute care facilities of NF/SGVHS and the use of a retrospective chart review. As a result, further research is necessary to establish generalizability to other acute care settings and high-risk populations. In spite of these limitations, this and other studies highlight the need for revision of the Braden scale, specifically the nutritional subscale, to lessen the ambiguity seen between dietitian and nursing assessments while also increasing the accuracy in determining a patient’s nutrition risk of PrU development during hospitalization.

Conclusion

These findings provide evidence that dietitians’ documentation of the VANCS related to nutritional compromise are superior to current nutritional risk assessments using the Braden nutrition subscale in predicting PrU risk.

Acknowledgments
The authors acknowledge that this work was supported by the resources of the North Florida/South Georgia Veterans Health System in Gainesville, Florida, and in part by a Small Project Award from the VA Office of Nursing Services.

A pressure ulcer (PrU) is a localized injury to the skin and/or deep tissues that is due to pressure, friction, or shearing forces. Pressure ulcers are strongly associated with serious comorbidities, particularly inadequate nutrition and immobility.^1,2 Pressure ulcers increase hospital costs significantly. In the U.S., PrU care is about $11 billion annually and a cost of between $2,000 and $21,410 per individual PrU.^3-5

The impact of nosocomial PrUs remains a key health and economic concern of acute care facilities worldwide. In the U.S., about 2.5 million inpatients annually develop some degree of a PrU during their hospital stay. The reported incidence rates range from 0.4% to 38%.^3,6 Each year about 60,000 people die of complications of a PrU.^3,6,7 Inadequate nutrition is a critical factor that contributes to the incidence of PrUs.^8-12 Consequences of inadequate nutrition have included alterations in skin integrity resulting in PrUs, longer hospital stays, increased costs of care, and higher rates of mortality.⁹ As a patient’s nutritional status becomes compromised, the likelihood of developing a PrU increases, especially if an individual is immobilized.^7,9-11,13

Braden Scale History

The Braden Scale for Predicting Pressure Sore Risk was developed by Barbara Braden, PhD, RN, and Nancy Bergstrom, PhD, RN, in 1987.^14,15 Originally established for use in long-term care facilities, the scale is recommended by the National Pressure Ulcer Advisory Panel in its clinical practice guidelines and is the most frequently used risk assessment tool by nurses in acute care facilities worldwide.¹

The scale is composed of 6 factors: sensory perception, moisture, activity, mobility, friction and shear, and nutrition.¹⁴ Each factor is scored on a scale of 1 to 4 points (friction and shear are scored on a point scale of only 1 to 3) for a total possible score of 6 to 23 points (the lower the score, the greater the assumed PrU risk).

The Braden nutrition subscale relies heavily on recording observed or patient self-reported eating habits. It is typically documented by nurses who assess the daily intake of meals: recording a score of 4 if the patient’s meal intake is excellent (eats most of every meal), 3 if the patient’s intake is adequate (eats more than half of most meals), 2 if the patient’s intake is probably inadequate (rarely eats a complete meal), and 1 if a patient’s intake is very poor (never eats a complete meal) (Table 1).¹⁴

Historically, the Braden scale is reported to have good reliability when used by registered nurses as a risk prediction tool.^14,16 A recent review also reported high interrater reliability of the Braden scale total score among nurses, nursing assistants, and graduate assistants.¹⁷ However, other studies suggest certain subscales (such as sensory and nutrition) may have very low interrater reliability among nurses and poor PrU predictability.^18,19 To date, there are no known studies evaluating the agreement of the Braden nutrition subscale primarily used by nurses and the VA Nutrition Classification Scheme (VANCS) used by dietitians.

The VA standard of care recommends that PrU risk assessments are documented for all hospitalized veterans within 24 hours of admission, daily, with transfers or discharges, and when there is a status change in the patient. In addition, nutritional assessments by dietitians (using the VANCS) are encouraged within 24 hours of acute care hospitalization.²⁰

The VANCS performed by dietitians consists of 4 classifications: no nutritional compromise, mild nutritional compromise, moderate nutritional compromise, and severenutritional compromise. These classifications are based on well-documented “comprehensive approaches to defining nutritional status that uses multiple parameters” including nutrition history, weight (body mass index and weight loss), diagnoses, diet (and diet orders), brief physical assessment, and preliminary laboratory data (serum albumin/pre-albumin and total lymphocyte count).^20,21

The predictive ability of a risk assessment tool is critical to its clinical effectiveness in determining a clinical outcome.¹⁷ The Braden scale has been used for more than 30 years in various settings without any significant change to the scale or subscales. In a 2012 study, 4 medical factors were found to be more predictive of PrUs than the Braden scale total score in a sample of 213 acutely ill adult veterans.⁸ By performing a retrospective study using logistic regression predictive models, severe nutritional compromise (as identified by a dietitian), pneumonia, candidiasis, and surgery were identified as stronger predictors of PrU risk than was the Braden total score.⁸

With malnutrition as one of the most significant predictive factors in PrU risk, it is critical to determine whether discrepancies exist between the Braden nutrition subscale used primarily by nurses and the VANCS used by dietitians. Hence, the overall purpose of this study was to determine the level of agreement between the Braden nutrition subscale scores documented by nurses and the VANCS used by dietitians and examine the relationship of these assessments with PrU development.

Methods

The parent study was approved by the University of Florida Institutional Review Board before data collection. This secondary analysis of the parent study examined data already collected by Cowan and colleagues, which demonstrated the significance of nutritional compromise in PrU risk.⁸

The de-identified data subset consisted of general demographics, hospital length of stay, specific diagnoses, Braden scores, PrU status, and registered dietician nutritional classification data from 213 acutely ill veterans admitted to North Florida/South Georgia Veterans Health System (NF/SGVHS) in Florida for more than 3 days between January and July 2008.⁸ The sample consisted of 100 veterans with nosocomial PrUs and 113 veterans without PrUs during their admission.

Scoring

Using the de-identified dataset, the variables of interest (VANCS, Braden nutrition subscale score, and the presence/absence of PrU) were coded. The VANCS was given a corresponding score ranging from 1 to 4 (1, severe nutritional compromise; 2, moderate nutritional compromise; 3, mild nutritional compromise; and 4, no nutritional compromise). The Braden nutrition subscale ranged from 1 to 4 (1 very poor nutrition; 2, probably inadequate nutrition; 3, adequate nutrition; and 4, excellent nutrition). PrU development was coded as 0, no PrU development and 1, PrU development. All nutritional assessments had been recorded in the electronic health record before any PrU reported in the parent study.

Statistical Analysis

After coding the variables of interest, the data were transferred into SAS v 9.4 (Cary, NC). The data collected compared VANCS and Braden nutrition subscale results. In addition, the authors examined the agreement between the score assigned to the VANCS and Braden nutrition subscale results with a weighted κ analysis. Further, to determine the relationship between PrU and each of the nutrition assessment methods, chi-square or Fisher exact tests were conducted. The level of significance was set at .05.

Additionally, the authors computed sensitivity and specificity of the Braden nutrition subscale using the VANCS as the gold standard. The severe and moderately compromised categories of the VANCS combined to form the high-risk category, and the mild-to-no compromise categories were combined to form the low-risk category. The Braden nutrition subscale was similarly dichotomized with the very poor and probably inadequate intake forming the high-risk category and the adequate and excellent intake forming the low-risk category. Sensitivity and specificity of the Braden were then calculated.

Results

Nursing assessments using the Braden nutrition subscale were completed on 213 patients whose mean age (SD) was 71.0 (10.6) years. The VANCS documented by dietitians was completed on 205 patients. For 7 patients, a nutrition assessment was documented only by the Braden nutrition subscale and not the VANCS. Most of the patients were male (97%, n = 206), and white (81.4%, n = 171). The weighted κ statistic used to measure agreement between the Braden nutrition subscale and the VANCS was .17 (95% confidence interval = .07, .28).

Landis and colleagues suggest that a κ value of .17 may be interpreted as “fair” agreement.²² Figure 1 shows the agreement seen between the Braden nutrition subscale and VANCS. There was no strong agreement identified. Within each VANCS (severe compromise, moderate compromise, mild compromise, or no compromise), the numbers of patients rated as 1 (very poor intake), 2 (intake probably inadequate), or 3 (intake adequate) on the Braden nutrition subscale is given.

Figure 2 shows the percentage of patients who developed a PrU during hospitalization among different measures of Braden nutrition subscale vs VANCS. In Figure 2, nutritional categories 1, 2, and 3 correspond to very poor intake (Braden)/severe compromise (VANCS), probably inadequate intake (Braden)/moderate compromise (VANCS), and adequate intake (Braden)/mild compromise (VANCS), respectively. There were 3 patients who had a no compromise VANCS; none of these had a PrU, so their data are not represented in Figure 2.

​

Discussion

Findings from this study indicate that the VANCS documented by dietitians is superior in assessing nutritional risk and predicting the development of PrUs in acutely ill hospitalized veterans compared with the Braden nutrition subscale. This study also shows that the Braden nutrition subscale did not accurately predict PrU development in acutely ill veterans. This finding concurs with the Serpa and Santos study in which the Braden nutrition subscale scores were not predictive for PrU development in hospitalized patients.²³ They found that serum albumin levels and subjective global nutrition assessments were superior nutritional predictors of PrU development. These findings suggest modifications or enhancements are needed to address how nurses assess nutritional risk for PrUs in hospitalized patients.

One possible explanation for the findings in this study is that the nutrition subscale of the Braden tool asks the assessing clinician to evaluate the amount of food intake the patient is currently taking in for their usual meals. This assessment is highly subjective and speculative and does not account for recent intake fluctuations or weight loss. By comparison, the VANCS is more comprehensive in its ability to assess nutritional compromise based on multiple factors, such as recent weight loss, laboratory indices, body habitus, dentition, and swallowing ability.²⁰ The National Pressure Ulcer Advisory Panel suggests that following an acute care admission, a patient receive a consult from a dietitian if the health care provider suspects that the patient may be nutritionally compromised.¹ The study findings demonstrate the utility of the VANCS as predictive of PrU risk.

Unfortunately, the authors have learned that the VANCS may be phased out soon, and many VA facilities are no longer using it. Findings from this study and other recent scientific literature suggest that all inpatients may benefit from nutritional assessments by dietitians. When performed, dietitian assessments provide the basis for more accurate nursing assessment of nutritional risk and targeted interventions. Nursing professionals should be encouraged to review the dietitian assessment and consultation notes and to incorporate this information into a more comprehensive PrU prevention and treatment plan.

Interestingly, in spite of those assessed to have severe nutritional compromise by dietitian assessment (n = 39), very few of these patients (n = 4) had an ICD-9 diagnosis related to malnutrition (ICD-9 codes, 262, 273.8, 269.9, 263.9) entered in their chart for that hospitalization. This observation suggests that 88% of patients with severe nutritional compromise were not appropriately coded at discharge. Improper coding has implications for researchers using ICD-9 diagnosis codes at discharge for accurate analysis of risk factors as well as for health care providers who may look at coded diagnoses information in the charts when considering comorbid conditions for health management.

This study highlights the importance of nutritional status as a risk factor for PrU development. Reasons suggested for nutritional status seeming to be the most significant correlate to PrUs in the acute care setting include the following: decreased protein alters oncotic pressure, making tissue prone to edema; decreases in subcutaneous fat reduce protection from pressure effects; nutritional compromise alters cellular transport of nutrients and waste and makes tissue cells more vulnerable to deformation and physical stresses; and lactate (a by-product of anaerobic glycolysis) or any other metabolic by-product of malnutrition could cause biochemical stress, and tissue cells can die faster as a result of the increased plasma membrane permeability.^7,24-26

Limitations

This study was limited to 1 sample of veterans hospitalized in the 2 acute care facilities of NF/SGVHS and the use of a retrospective chart review. As a result, further research is necessary to establish generalizability to other acute care settings and high-risk populations. In spite of these limitations, this and other studies highlight the need for revision of the Braden scale, specifically the nutritional subscale, to lessen the ambiguity seen between dietitian and nursing assessments while also increasing the accuracy in determining a patient’s nutrition risk of PrU development during hospitalization.

Conclusion

These findings provide evidence that dietitians’ documentation of the VANCS related to nutritional compromise are superior to current nutritional risk assessments using the Braden nutrition subscale in predicting PrU risk.

Acknowledgments
The authors acknowledge that this work was supported by the resources of the North Florida/South Georgia Veterans Health System in Gainesville, Florida, and in part by a Small Project Award from the VA Office of Nursing Services.

A pressure ulcer (PrU) is a localized injury to the skin and/or deep tissues that is due to pressure, friction, or shearing forces. Pressure ulcers are strongly associated with serious comorbidities, particularly inadequate nutrition and immobility.^1,2 Pressure ulcers increase hospital costs significantly. In the U.S., PrU care is about $11 billion annually and a cost of between $2,000 and $21,410 per individual PrU.^3-5

The impact of nosocomial PrUs remains a key health and economic concern of acute care facilities worldwide. In the U.S., about 2.5 million inpatients annually develop some degree of a PrU during their hospital stay. The reported incidence rates range from 0.4% to 38%.^3,6 Each year about 60,000 people die of complications of a PrU.^3,6,7 Inadequate nutrition is a critical factor that contributes to the incidence of PrUs.^8-12 Consequences of inadequate nutrition have included alterations in skin integrity resulting in PrUs, longer hospital stays, increased costs of care, and higher rates of mortality.⁹ As a patient’s nutritional status becomes compromised, the likelihood of developing a PrU increases, especially if an individual is immobilized.^7,9-11,13

Braden Scale History

The Braden Scale for Predicting Pressure Sore Risk was developed by Barbara Braden, PhD, RN, and Nancy Bergstrom, PhD, RN, in 1987.^14,15 Originally established for use in long-term care facilities, the scale is recommended by the National Pressure Ulcer Advisory Panel in its clinical practice guidelines and is the most frequently used risk assessment tool by nurses in acute care facilities worldwide.¹

The scale is composed of 6 factors: sensory perception, moisture, activity, mobility, friction and shear, and nutrition.¹⁴ Each factor is scored on a scale of 1 to 4 points (friction and shear are scored on a point scale of only 1 to 3) for a total possible score of 6 to 23 points (the lower the score, the greater the assumed PrU risk).

The Braden nutrition subscale relies heavily on recording observed or patient self-reported eating habits. It is typically documented by nurses who assess the daily intake of meals: recording a score of 4 if the patient’s meal intake is excellent (eats most of every meal), 3 if the patient’s intake is adequate (eats more than half of most meals), 2 if the patient’s intake is probably inadequate (rarely eats a complete meal), and 1 if a patient’s intake is very poor (never eats a complete meal) (Table 1).¹⁴

Historically, the Braden scale is reported to have good reliability when used by registered nurses as a risk prediction tool.^14,16 A recent review also reported high interrater reliability of the Braden scale total score among nurses, nursing assistants, and graduate assistants.¹⁷ However, other studies suggest certain subscales (such as sensory and nutrition) may have very low interrater reliability among nurses and poor PrU predictability.^18,19 To date, there are no known studies evaluating the agreement of the Braden nutrition subscale primarily used by nurses and the VA Nutrition Classification Scheme (VANCS) used by dietitians.

The VA standard of care recommends that PrU risk assessments are documented for all hospitalized veterans within 24 hours of admission, daily, with transfers or discharges, and when there is a status change in the patient. In addition, nutritional assessments by dietitians (using the VANCS) are encouraged within 24 hours of acute care hospitalization.²⁰

The VANCS performed by dietitians consists of 4 classifications: no nutritional compromise, mild nutritional compromise, moderate nutritional compromise, and severenutritional compromise. These classifications are based on well-documented “comprehensive approaches to defining nutritional status that uses multiple parameters” including nutrition history, weight (body mass index and weight loss), diagnoses, diet (and diet orders), brief physical assessment, and preliminary laboratory data (serum albumin/pre-albumin and total lymphocyte count).^20,21

The predictive ability of a risk assessment tool is critical to its clinical effectiveness in determining a clinical outcome.¹⁷ The Braden scale has been used for more than 30 years in various settings without any significant change to the scale or subscales. In a 2012 study, 4 medical factors were found to be more predictive of PrUs than the Braden scale total score in a sample of 213 acutely ill adult veterans.⁸ By performing a retrospective study using logistic regression predictive models, severe nutritional compromise (as identified by a dietitian), pneumonia, candidiasis, and surgery were identified as stronger predictors of PrU risk than was the Braden total score.⁸

With malnutrition as one of the most significant predictive factors in PrU risk, it is critical to determine whether discrepancies exist between the Braden nutrition subscale used primarily by nurses and the VANCS used by dietitians. Hence, the overall purpose of this study was to determine the level of agreement between the Braden nutrition subscale scores documented by nurses and the VANCS used by dietitians and examine the relationship of these assessments with PrU development.

Methods

The parent study was approved by the University of Florida Institutional Review Board before data collection. This secondary analysis of the parent study examined data already collected by Cowan and colleagues, which demonstrated the significance of nutritional compromise in PrU risk.⁸

The de-identified data subset consisted of general demographics, hospital length of stay, specific diagnoses, Braden scores, PrU status, and registered dietician nutritional classification data from 213 acutely ill veterans admitted to North Florida/South Georgia Veterans Health System (NF/SGVHS) in Florida for more than 3 days between January and July 2008.⁸ The sample consisted of 100 veterans with nosocomial PrUs and 113 veterans without PrUs during their admission.

Scoring

Using the de-identified dataset, the variables of interest (VANCS, Braden nutrition subscale score, and the presence/absence of PrU) were coded. The VANCS was given a corresponding score ranging from 1 to 4 (1, severe nutritional compromise; 2, moderate nutritional compromise; 3, mild nutritional compromise; and 4, no nutritional compromise). The Braden nutrition subscale ranged from 1 to 4 (1 very poor nutrition; 2, probably inadequate nutrition; 3, adequate nutrition; and 4, excellent nutrition). PrU development was coded as 0, no PrU development and 1, PrU development. All nutritional assessments had been recorded in the electronic health record before any PrU reported in the parent study.

Statistical Analysis

After coding the variables of interest, the data were transferred into SAS v 9.4 (Cary, NC). The data collected compared VANCS and Braden nutrition subscale results. In addition, the authors examined the agreement between the score assigned to the VANCS and Braden nutrition subscale results with a weighted κ analysis. Further, to determine the relationship between PrU and each of the nutrition assessment methods, chi-square or Fisher exact tests were conducted. The level of significance was set at .05.

Additionally, the authors computed sensitivity and specificity of the Braden nutrition subscale using the VANCS as the gold standard. The severe and moderately compromised categories of the VANCS combined to form the high-risk category, and the mild-to-no compromise categories were combined to form the low-risk category. The Braden nutrition subscale was similarly dichotomized with the very poor and probably inadequate intake forming the high-risk category and the adequate and excellent intake forming the low-risk category. Sensitivity and specificity of the Braden were then calculated.

Results

Nursing assessments using the Braden nutrition subscale were completed on 213 patients whose mean age (SD) was 71.0 (10.6) years. The VANCS documented by dietitians was completed on 205 patients. For 7 patients, a nutrition assessment was documented only by the Braden nutrition subscale and not the VANCS. Most of the patients were male (97%, n = 206), and white (81.4%, n = 171). The weighted κ statistic used to measure agreement between the Braden nutrition subscale and the VANCS was .17 (95% confidence interval = .07, .28).

Landis and colleagues suggest that a κ value of .17 may be interpreted as “fair” agreement.²² Figure 1 shows the agreement seen between the Braden nutrition subscale and VANCS. There was no strong agreement identified. Within each VANCS (severe compromise, moderate compromise, mild compromise, or no compromise), the numbers of patients rated as 1 (very poor intake), 2 (intake probably inadequate), or 3 (intake adequate) on the Braden nutrition subscale is given.

Figure 2 shows the percentage of patients who developed a PrU during hospitalization among different measures of Braden nutrition subscale vs VANCS. In Figure 2, nutritional categories 1, 2, and 3 correspond to very poor intake (Braden)/severe compromise (VANCS), probably inadequate intake (Braden)/moderate compromise (VANCS), and adequate intake (Braden)/mild compromise (VANCS), respectively. There were 3 patients who had a no compromise VANCS; none of these had a PrU, so their data are not represented in Figure 2.

​

Discussion

Findings from this study indicate that the VANCS documented by dietitians is superior in assessing nutritional risk and predicting the development of PrUs in acutely ill hospitalized veterans compared with the Braden nutrition subscale. This study also shows that the Braden nutrition subscale did not accurately predict PrU development in acutely ill veterans. This finding concurs with the Serpa and Santos study in which the Braden nutrition subscale scores were not predictive for PrU development in hospitalized patients.²³ They found that serum albumin levels and subjective global nutrition assessments were superior nutritional predictors of PrU development. These findings suggest modifications or enhancements are needed to address how nurses assess nutritional risk for PrUs in hospitalized patients.

One possible explanation for the findings in this study is that the nutrition subscale of the Braden tool asks the assessing clinician to evaluate the amount of food intake the patient is currently taking in for their usual meals. This assessment is highly subjective and speculative and does not account for recent intake fluctuations or weight loss. By comparison, the VANCS is more comprehensive in its ability to assess nutritional compromise based on multiple factors, such as recent weight loss, laboratory indices, body habitus, dentition, and swallowing ability.²⁰ The National Pressure Ulcer Advisory Panel suggests that following an acute care admission, a patient receive a consult from a dietitian if the health care provider suspects that the patient may be nutritionally compromised.¹ The study findings demonstrate the utility of the VANCS as predictive of PrU risk.

Unfortunately, the authors have learned that the VANCS may be phased out soon, and many VA facilities are no longer using it. Findings from this study and other recent scientific literature suggest that all inpatients may benefit from nutritional assessments by dietitians. When performed, dietitian assessments provide the basis for more accurate nursing assessment of nutritional risk and targeted interventions. Nursing professionals should be encouraged to review the dietitian assessment and consultation notes and to incorporate this information into a more comprehensive PrU prevention and treatment plan.

Interestingly, in spite of those assessed to have severe nutritional compromise by dietitian assessment (n = 39), very few of these patients (n = 4) had an ICD-9 diagnosis related to malnutrition (ICD-9 codes, 262, 273.8, 269.9, 263.9) entered in their chart for that hospitalization. This observation suggests that 88% of patients with severe nutritional compromise were not appropriately coded at discharge. Improper coding has implications for researchers using ICD-9 diagnosis codes at discharge for accurate analysis of risk factors as well as for health care providers who may look at coded diagnoses information in the charts when considering comorbid conditions for health management.

This study highlights the importance of nutritional status as a risk factor for PrU development. Reasons suggested for nutritional status seeming to be the most significant correlate to PrUs in the acute care setting include the following: decreased protein alters oncotic pressure, making tissue prone to edema; decreases in subcutaneous fat reduce protection from pressure effects; nutritional compromise alters cellular transport of nutrients and waste and makes tissue cells more vulnerable to deformation and physical stresses; and lactate (a by-product of anaerobic glycolysis) or any other metabolic by-product of malnutrition could cause biochemical stress, and tissue cells can die faster as a result of the increased plasma membrane permeability.^7,24-26

Limitations

This study was limited to 1 sample of veterans hospitalized in the 2 acute care facilities of NF/SGVHS and the use of a retrospective chart review. As a result, further research is necessary to establish generalizability to other acute care settings and high-risk populations. In spite of these limitations, this and other studies highlight the need for revision of the Braden scale, specifically the nutritional subscale, to lessen the ambiguity seen between dietitian and nursing assessments while also increasing the accuracy in determining a patient’s nutrition risk of PrU development during hospitalization.

Conclusion

These findings provide evidence that dietitians’ documentation of the VANCS related to nutritional compromise are superior to current nutritional risk assessments using the Braden nutrition subscale in predicting PrU risk.

Acknowledgments
The authors acknowledge that this work was supported by the resources of the North Florida/South Georgia Veterans Health System in Gainesville, Florida, and in part by a Small Project Award from the VA Office of Nursing Services.

Jacqueline Mays, DDS, PhD

Photo courtesy of NIH

SAN DIEGO—Results of a phase 2 study suggest an oral mouth rinse formulation of the steroid clobetasol could provide short-term treatment of oral chronic graft-vs-host disease (cGVHD).

A majority of patients had a greater than 25% improvement in their cGVHD after using the clobetasol rinse, and patients reported improvements in oral health-related quality of life.

The rinse even proved effective in patients who had failed prior treatment with clobetasol ointment.

However, researchers found evidence to suggest the clobetasol rinse is not suitable for unmonitored, long-term use, as some patients experienced adrenal suppression.

Jacqueline W. Mays, DDS, PhD, of the National Institutes of Health (NIH) in Bethesda, Maryland, presented these findings at the 2016 ASH Annual Meeting (abstract 826).

Dr Mays noted that topical therapy for oral cGVHD is intended to spare patients from exposure to systemic immunosuppressive agents.

According to NIH consensus criteria, dexamethasone is recommended as the first-line topical therapy for these patients. However, clinical trial data suggest only 29% to 58% of patients respond to this therapy.

Second-line treatment is not well-established, but it typically consists of topical steroids in a gel or ointment formulation. Unfortunately, patient compliance is an issue with this type of treatment.

“If you can imagine trying to apply something in a petrolatum base to the inside of your very wet wall cavity, you can imagine that’s a challenge for a healthy individual, much less for a chronic graft-vs-host disease patient who often will have joint mobility and fine motor issues,” Dr Mays said.

“So this leads to frequent treatment failures of topical regimens, not only due to the drug agents but also due to patient compliance.”

Dr Mays noted that clobetasol is a superpotent synthetic glucocorticoid that has been used off-label in ointment form to treat refractory oral GVHD.

In an attempt to overcome the application challenges with this ointment and improve patient adherence to oral cGVHD treatment, Dr Mays and her colleagues decided to investigate a clobetasol 0.05% solution formulated as an oral rinse in an aqueous base.

The team tested the rinse in a phase 2 trial with an initial 2-week randomized, double-blind, placebo-controlled period.

Patient population

The trial enrolled and randomized 36 patients with oral cGVHD. The patients had an Oral Mucositis Rating Scale (OMRS) score of ≥20 with moderate erythema and/or ulceration. They also had stable or tapering systemic therapy during the 2 weeks prior to starting the study and for the duration of the blinded period.

The patients’ median age was 42 (range, 18-68), and 20 were male. Thirty-five patients received ablative conditioning, 18 received a related-donor transplant, 34 received a matched-donor transplant, and 30 received a peripheral blood stem cell graft.

The median time from cGVHD diagnosis to trial enrollment was 257 days (range, 15-3013). Thirty-six patients had mouth cGVHD, 21 had skin cGVHD, 26 had eye cGVHD, 14 had gastrointestinal cGVHD, 16 had liver cGVHD, 11 had lung cGVHD, and 10 had cGVHD of the joints and fascia.

Six patients had not received any prior oral topical therapy. The other 30 patients had a median of 2 prior oral topical therapies. Eleven patients had received prior clobetasol ointment.

Treatment

The patients were randomized to receive clobetasol or placebo rinse for 2 weeks (blinded period). After that, all patients received clobetasol rinse until they completed 28 days of treatment.

The patients were required to perform a 2-minute swish with 10 ml of clobetasol rinse 3 times daily and a once-daily swish with nystatin (100,000 u/ml) rinse for antifungal prophylaxis. The patients continued on systemic pneumocystis, antiviral, and antifungal prophylaxis, per NIH cGVHD guidelines.

Thirty-two of the patients completed treatment, using the clobetasol rinse for the full 28 days.

Four patients went off study before completing 28 days of treatment. One of these patients could not tolerate the rinse. This patient had gastrointestinal issues that were attributed (by the patient and the physician) to use of the study drug.

Two patients went off study because they could not make it to the NIH for follow-up visits, and 1 patient died. The death was unrelated to the study drug.

Safety

Dr Mays noted that small amounts of clobetasol were detectable in the bloodstream, but she and her colleagues found this was not directly correlated to patient serum cortisol levels.

However, the researchers did observe a significant drop in serum cortisol levels from baseline to day 28, suggesting the rinse has an adrenal impact.

On the other hand, the peripheral lymphocyte profile was unchanged by the use of clobetasol rinse, which suggests there were no significant systemic immunosuppressive effects.

Adverse events considered possibly or probably related to clobetasol rinse included herpes simplex virus reactivation (n=3, grade 2-3), oral candidiasis (n=3, grade 2), other oral viral infection (n=1, grade 2), facial edema (n=3, grade 1), and adrenal suppression (6 grade 1 and 1 grade 2).

Dr Mays noted that many of the patients came on the study with adrenal suppression, but the clobetasol rinse had an additional impact.

Efficacy

The study’s primary endpoint was change in oral cGVHD severity scale at day 28 compared to baseline. Complete response was defined as a score of 0 on the erythema and ulceration components. Partial response was defined as a 25% decrease in score.

Progression was defined as a 25% increase in initial score. Stable disease was defined as a status that does not meet the criteria for progression or response.

Ninety-one percent of patients had a greater than 25% improvement in oral cGVHD severity scale. Nineteen percent of patients had a complete response, 72% of patients had a partial response, and 9% had stable disease. None of the patients progressed.

Dr Mays noted that patients who failed treatment with prior clobetasol ointment responded similarly to the clobetasol rinse when compared with the full study cohort.

Among the 11 patients with prior clobetasol ointment, 18% had a complete response, 73% had a partial response, 9% had stable disease, and none progressed.

Clobetasol rinse significantly decreased the clinical OMRS score (P<0.0001) and improved cGVHD pathology diagnosis (P=0.0001).

Patients reported a significant improvement in oral health-based quality of life (P=0.0008) after completing treatment, as well as significant improvements in oral pain (P=0.017) and oral sensitivity (P=0.0081).

Though saliva production did not change significantly from baseline to day 28, patients reported a significant improvement in oral dryness (P=0.014).

The blinded period of the study showed that placebo treatment was not effective. There was a significant difference between the placebo and clobetasol groups with regard to improvement in OMRS score from baseline to day 14 (P=0.0031).

“We found clobetasol oral rinse to be both effective and safe for short-term treatment of oral mucosal cGVHD and hope that it will improve sparing of systemic immunosuppressants in this patient population,” Dr Mays said. “Its risk profile is generally not suitable for unmonitored, long-term use.”

Jacqueline Mays, DDS, PhD

Photo courtesy of NIH

SAN DIEGO—Results of a phase 2 study suggest an oral mouth rinse formulation of the steroid clobetasol could provide short-term treatment of oral chronic graft-vs-host disease (cGVHD).

A majority of patients had a greater than 25% improvement in their cGVHD after using the clobetasol rinse, and patients reported improvements in oral health-related quality of life.

The rinse even proved effective in patients who had failed prior treatment with clobetasol ointment.

However, researchers found evidence to suggest the clobetasol rinse is not suitable for unmonitored, long-term use, as some patients experienced adrenal suppression.

Jacqueline W. Mays, DDS, PhD, of the National Institutes of Health (NIH) in Bethesda, Maryland, presented these findings at the 2016 ASH Annual Meeting (abstract 826).

Dr Mays noted that topical therapy for oral cGVHD is intended to spare patients from exposure to systemic immunosuppressive agents.

According to NIH consensus criteria, dexamethasone is recommended as the first-line topical therapy for these patients. However, clinical trial data suggest only 29% to 58% of patients respond to this therapy.

Second-line treatment is not well-established, but it typically consists of topical steroids in a gel or ointment formulation. Unfortunately, patient compliance is an issue with this type of treatment.

“If you can imagine trying to apply something in a petrolatum base to the inside of your very wet wall cavity, you can imagine that’s a challenge for a healthy individual, much less for a chronic graft-vs-host disease patient who often will have joint mobility and fine motor issues,” Dr Mays said.

“So this leads to frequent treatment failures of topical regimens, not only due to the drug agents but also due to patient compliance.”

Dr Mays noted that clobetasol is a superpotent synthetic glucocorticoid that has been used off-label in ointment form to treat refractory oral GVHD.

In an attempt to overcome the application challenges with this ointment and improve patient adherence to oral cGVHD treatment, Dr Mays and her colleagues decided to investigate a clobetasol 0.05% solution formulated as an oral rinse in an aqueous base.

The team tested the rinse in a phase 2 trial with an initial 2-week randomized, double-blind, placebo-controlled period.

Patient population

The trial enrolled and randomized 36 patients with oral cGVHD. The patients had an Oral Mucositis Rating Scale (OMRS) score of ≥20 with moderate erythema and/or ulceration. They also had stable or tapering systemic therapy during the 2 weeks prior to starting the study and for the duration of the blinded period.

The patients’ median age was 42 (range, 18-68), and 20 were male. Thirty-five patients received ablative conditioning, 18 received a related-donor transplant, 34 received a matched-donor transplant, and 30 received a peripheral blood stem cell graft.

The median time from cGVHD diagnosis to trial enrollment was 257 days (range, 15-3013). Thirty-six patients had mouth cGVHD, 21 had skin cGVHD, 26 had eye cGVHD, 14 had gastrointestinal cGVHD, 16 had liver cGVHD, 11 had lung cGVHD, and 10 had cGVHD of the joints and fascia.

Six patients had not received any prior oral topical therapy. The other 30 patients had a median of 2 prior oral topical therapies. Eleven patients had received prior clobetasol ointment.

Treatment

The patients were randomized to receive clobetasol or placebo rinse for 2 weeks (blinded period). After that, all patients received clobetasol rinse until they completed 28 days of treatment.

The patients were required to perform a 2-minute swish with 10 ml of clobetasol rinse 3 times daily and a once-daily swish with nystatin (100,000 u/ml) rinse for antifungal prophylaxis. The patients continued on systemic pneumocystis, antiviral, and antifungal prophylaxis, per NIH cGVHD guidelines.

Thirty-two of the patients completed treatment, using the clobetasol rinse for the full 28 days.

Four patients went off study before completing 28 days of treatment. One of these patients could not tolerate the rinse. This patient had gastrointestinal issues that were attributed (by the patient and the physician) to use of the study drug.

Two patients went off study because they could not make it to the NIH for follow-up visits, and 1 patient died. The death was unrelated to the study drug.

Safety

Dr Mays noted that small amounts of clobetasol were detectable in the bloodstream, but she and her colleagues found this was not directly correlated to patient serum cortisol levels.

However, the researchers did observe a significant drop in serum cortisol levels from baseline to day 28, suggesting the rinse has an adrenal impact.

On the other hand, the peripheral lymphocyte profile was unchanged by the use of clobetasol rinse, which suggests there were no significant systemic immunosuppressive effects.

Adverse events considered possibly or probably related to clobetasol rinse included herpes simplex virus reactivation (n=3, grade 2-3), oral candidiasis (n=3, grade 2), other oral viral infection (n=1, grade 2), facial edema (n=3, grade 1), and adrenal suppression (6 grade 1 and 1 grade 2).

Dr Mays noted that many of the patients came on the study with adrenal suppression, but the clobetasol rinse had an additional impact.

Efficacy

The study’s primary endpoint was change in oral cGVHD severity scale at day 28 compared to baseline. Complete response was defined as a score of 0 on the erythema and ulceration components. Partial response was defined as a 25% decrease in score.

Progression was defined as a 25% increase in initial score. Stable disease was defined as a status that does not meet the criteria for progression or response.

Ninety-one percent of patients had a greater than 25% improvement in oral cGVHD severity scale. Nineteen percent of patients had a complete response, 72% of patients had a partial response, and 9% had stable disease. None of the patients progressed.

Dr Mays noted that patients who failed treatment with prior clobetasol ointment responded similarly to the clobetasol rinse when compared with the full study cohort.

Among the 11 patients with prior clobetasol ointment, 18% had a complete response, 73% had a partial response, 9% had stable disease, and none progressed.

Clobetasol rinse significantly decreased the clinical OMRS score (P<0.0001) and improved cGVHD pathology diagnosis (P=0.0001).

Patients reported a significant improvement in oral health-based quality of life (P=0.0008) after completing treatment, as well as significant improvements in oral pain (P=0.017) and oral sensitivity (P=0.0081).

Though saliva production did not change significantly from baseline to day 28, patients reported a significant improvement in oral dryness (P=0.014).

The blinded period of the study showed that placebo treatment was not effective. There was a significant difference between the placebo and clobetasol groups with regard to improvement in OMRS score from baseline to day 14 (P=0.0031).

“We found clobetasol oral rinse to be both effective and safe for short-term treatment of oral mucosal cGVHD and hope that it will improve sparing of systemic immunosuppressants in this patient population,” Dr Mays said. “Its risk profile is generally not suitable for unmonitored, long-term use.”

Jacqueline Mays, DDS, PhD

Photo courtesy of NIH

SAN DIEGO—Results of a phase 2 study suggest an oral mouth rinse formulation of the steroid clobetasol could provide short-term treatment of oral chronic graft-vs-host disease (cGVHD).

A majority of patients had a greater than 25% improvement in their cGVHD after using the clobetasol rinse, and patients reported improvements in oral health-related quality of life.

The rinse even proved effective in patients who had failed prior treatment with clobetasol ointment.

However, researchers found evidence to suggest the clobetasol rinse is not suitable for unmonitored, long-term use, as some patients experienced adrenal suppression.

Jacqueline W. Mays, DDS, PhD, of the National Institutes of Health (NIH) in Bethesda, Maryland, presented these findings at the 2016 ASH Annual Meeting (abstract 826).

Dr Mays noted that topical therapy for oral cGVHD is intended to spare patients from exposure to systemic immunosuppressive agents.

According to NIH consensus criteria, dexamethasone is recommended as the first-line topical therapy for these patients. However, clinical trial data suggest only 29% to 58% of patients respond to this therapy.

Second-line treatment is not well-established, but it typically consists of topical steroids in a gel or ointment formulation. Unfortunately, patient compliance is an issue with this type of treatment.

“If you can imagine trying to apply something in a petrolatum base to the inside of your very wet wall cavity, you can imagine that’s a challenge for a healthy individual, much less for a chronic graft-vs-host disease patient who often will have joint mobility and fine motor issues,” Dr Mays said.

“So this leads to frequent treatment failures of topical regimens, not only due to the drug agents but also due to patient compliance.”

Dr Mays noted that clobetasol is a superpotent synthetic glucocorticoid that has been used off-label in ointment form to treat refractory oral GVHD.

In an attempt to overcome the application challenges with this ointment and improve patient adherence to oral cGVHD treatment, Dr Mays and her colleagues decided to investigate a clobetasol 0.05% solution formulated as an oral rinse in an aqueous base.

The team tested the rinse in a phase 2 trial with an initial 2-week randomized, double-blind, placebo-controlled period.

Patient population

The trial enrolled and randomized 36 patients with oral cGVHD. The patients had an Oral Mucositis Rating Scale (OMRS) score of ≥20 with moderate erythema and/or ulceration. They also had stable or tapering systemic therapy during the 2 weeks prior to starting the study and for the duration of the blinded period.

The patients’ median age was 42 (range, 18-68), and 20 were male. Thirty-five patients received ablative conditioning, 18 received a related-donor transplant, 34 received a matched-donor transplant, and 30 received a peripheral blood stem cell graft.

The median time from cGVHD diagnosis to trial enrollment was 257 days (range, 15-3013). Thirty-six patients had mouth cGVHD, 21 had skin cGVHD, 26 had eye cGVHD, 14 had gastrointestinal cGVHD, 16 had liver cGVHD, 11 had lung cGVHD, and 10 had cGVHD of the joints and fascia.

Six patients had not received any prior oral topical therapy. The other 30 patients had a median of 2 prior oral topical therapies. Eleven patients had received prior clobetasol ointment.

Treatment

The patients were randomized to receive clobetasol or placebo rinse for 2 weeks (blinded period). After that, all patients received clobetasol rinse until they completed 28 days of treatment.

The patients were required to perform a 2-minute swish with 10 ml of clobetasol rinse 3 times daily and a once-daily swish with nystatin (100,000 u/ml) rinse for antifungal prophylaxis. The patients continued on systemic pneumocystis, antiviral, and antifungal prophylaxis, per NIH cGVHD guidelines.

Thirty-two of the patients completed treatment, using the clobetasol rinse for the full 28 days.

Four patients went off study before completing 28 days of treatment. One of these patients could not tolerate the rinse. This patient had gastrointestinal issues that were attributed (by the patient and the physician) to use of the study drug.

Two patients went off study because they could not make it to the NIH for follow-up visits, and 1 patient died. The death was unrelated to the study drug.

Safety

Dr Mays noted that small amounts of clobetasol were detectable in the bloodstream, but she and her colleagues found this was not directly correlated to patient serum cortisol levels.

However, the researchers did observe a significant drop in serum cortisol levels from baseline to day 28, suggesting the rinse has an adrenal impact.

On the other hand, the peripheral lymphocyte profile was unchanged by the use of clobetasol rinse, which suggests there were no significant systemic immunosuppressive effects.

Adverse events considered possibly or probably related to clobetasol rinse included herpes simplex virus reactivation (n=3, grade 2-3), oral candidiasis (n=3, grade 2), other oral viral infection (n=1, grade 2), facial edema (n=3, grade 1), and adrenal suppression (6 grade 1 and 1 grade 2).

Dr Mays noted that many of the patients came on the study with adrenal suppression, but the clobetasol rinse had an additional impact.

Efficacy

The study’s primary endpoint was change in oral cGVHD severity scale at day 28 compared to baseline. Complete response was defined as a score of 0 on the erythema and ulceration components. Partial response was defined as a 25% decrease in score.

Progression was defined as a 25% increase in initial score. Stable disease was defined as a status that does not meet the criteria for progression or response.

Ninety-one percent of patients had a greater than 25% improvement in oral cGVHD severity scale. Nineteen percent of patients had a complete response, 72% of patients had a partial response, and 9% had stable disease. None of the patients progressed.

Dr Mays noted that patients who failed treatment with prior clobetasol ointment responded similarly to the clobetasol rinse when compared with the full study cohort.

Among the 11 patients with prior clobetasol ointment, 18% had a complete response, 73% had a partial response, 9% had stable disease, and none progressed.

Clobetasol rinse significantly decreased the clinical OMRS score (P<0.0001) and improved cGVHD pathology diagnosis (P=0.0001).

Patients reported a significant improvement in oral health-based quality of life (P=0.0008) after completing treatment, as well as significant improvements in oral pain (P=0.017) and oral sensitivity (P=0.0081).

Though saliva production did not change significantly from baseline to day 28, patients reported a significant improvement in oral dryness (P=0.014).

The blinded period of the study showed that placebo treatment was not effective. There was a significant difference between the placebo and clobetasol groups with regard to improvement in OMRS score from baseline to day 14 (P=0.0031).

“We found clobetasol oral rinse to be both effective and safe for short-term treatment of oral mucosal cGVHD and hope that it will improve sparing of systemic immunosuppressants in this patient population,” Dr Mays said. “Its risk profile is generally not suitable for unmonitored, long-term use.”

Skeletal remains of an

individual from Velia, Italy

Photo courtesy of Luca

Bandioli, Pigorini Museum

An analysis of 2000-year-old human remains from several regions across the Italian peninsula has confirmed the presence of Plasmodium falciparum malaria during the Roman Empire, according to researchers.

The team found mitochondrial genomic evidence of P falciparum malaria, coaxed from the teeth of bodies buried in 3 Italian cemeteries, dating back to the Imperial period.

The researchers said these finding provide a key reference point for when and where the malaria parasite existed in humans, as well as more information about the evolution of human disease.

The team reported these findings in Current Biology.

“There is extensive written evidence describing fevers that sound like malaria in ancient Greece and Rome, but the specific malaria species responsible is unknown,” said study author Stephanie Marciniak, PhD, of Pennsylvania State University in University Park.

“Our data confirm that the species was likely Plasmodium falciparum and that it affected people in different ecological and cultural environments. These results open up new questions to explore, particularly how widespread this parasite was and what burden it placed upon communities in Imperial Roman Italy.”

Dr Marciniak and her colleagues sampled teeth taken from 58 adults interred at 3 Imperial period Italian cemeteries: Isola Sacra, Velia, and Vagnari.

Located on the coast, Velia and Isola Sacra were known as important port cities and trading centers. Vagnari is located further inland and believed to be the burial site of laborers who would have worked on a Roman rural estate.

The researchers mined tiny DNA fragments from dental pulp. They were able to extract, purify, and enrich specifically for the Plasmodium species known to infect humans.

The team noted that usable DNA is challenging to extract because the parasites primarily dwell within the bloodstream and organs, which decompose and break down over time—in this instance, over the course of 2 millennia.

However, the researchers recovered more than half of the P falciparum mitochondrial genome from 2 individuals from Velia and Vagnari.

Skeletal remains of an

individual from Velia, Italy

Photo courtesy of Luca

Bandioli, Pigorini Museum

An analysis of 2000-year-old human remains from several regions across the Italian peninsula has confirmed the presence of Plasmodium falciparum malaria during the Roman Empire, according to researchers.

The team found mitochondrial genomic evidence of P falciparum malaria, coaxed from the teeth of bodies buried in 3 Italian cemeteries, dating back to the Imperial period.

The researchers said these finding provide a key reference point for when and where the malaria parasite existed in humans, as well as more information about the evolution of human disease.

The team reported these findings in Current Biology.

“There is extensive written evidence describing fevers that sound like malaria in ancient Greece and Rome, but the specific malaria species responsible is unknown,” said study author Stephanie Marciniak, PhD, of Pennsylvania State University in University Park.

“Our data confirm that the species was likely Plasmodium falciparum and that it affected people in different ecological and cultural environments. These results open up new questions to explore, particularly how widespread this parasite was and what burden it placed upon communities in Imperial Roman Italy.”

Dr Marciniak and her colleagues sampled teeth taken from 58 adults interred at 3 Imperial period Italian cemeteries: Isola Sacra, Velia, and Vagnari.

Located on the coast, Velia and Isola Sacra were known as important port cities and trading centers. Vagnari is located further inland and believed to be the burial site of laborers who would have worked on a Roman rural estate.

The researchers mined tiny DNA fragments from dental pulp. They were able to extract, purify, and enrich specifically for the Plasmodium species known to infect humans.

The team noted that usable DNA is challenging to extract because the parasites primarily dwell within the bloodstream and organs, which decompose and break down over time—in this instance, over the course of 2 millennia.

However, the researchers recovered more than half of the P falciparum mitochondrial genome from 2 individuals from Velia and Vagnari.

Skeletal remains of an

individual from Velia, Italy

Photo courtesy of Luca

Bandioli, Pigorini Museum

An analysis of 2000-year-old human remains from several regions across the Italian peninsula has confirmed the presence of Plasmodium falciparum malaria during the Roman Empire, according to researchers.

The team found mitochondrial genomic evidence of P falciparum malaria, coaxed from the teeth of bodies buried in 3 Italian cemeteries, dating back to the Imperial period.

The researchers said these finding provide a key reference point for when and where the malaria parasite existed in humans, as well as more information about the evolution of human disease.

The team reported these findings in Current Biology.

“There is extensive written evidence describing fevers that sound like malaria in ancient Greece and Rome, but the specific malaria species responsible is unknown,” said study author Stephanie Marciniak, PhD, of Pennsylvania State University in University Park.

“Our data confirm that the species was likely Plasmodium falciparum and that it affected people in different ecological and cultural environments. These results open up new questions to explore, particularly how widespread this parasite was and what burden it placed upon communities in Imperial Roman Italy.”

Dr Marciniak and her colleagues sampled teeth taken from 58 adults interred at 3 Imperial period Italian cemeteries: Isola Sacra, Velia, and Vagnari.

Located on the coast, Velia and Isola Sacra were known as important port cities and trading centers. Vagnari is located further inland and believed to be the burial site of laborers who would have worked on a Roman rural estate.

The researchers mined tiny DNA fragments from dental pulp. They were able to extract, purify, and enrich specifically for the Plasmodium species known to infect humans.

The team noted that usable DNA is challenging to extract because the parasites primarily dwell within the bloodstream and organs, which decompose and break down over time—in this instance, over the course of 2 millennia.

However, the researchers recovered more than half of the P falciparum mitochondrial genome from 2 individuals from Velia and Vagnari.

Partnerships between community emergency departments and pediatric tertiary care centers are feasible and improve care of pediatric asthma, according to Theresa A. Walls, MD, of the Children’s National Health Systems, Washington, D.C., and her associates.

A total of 724 asthma patients aged 2-17 years were included in the study. Of this group, 289 (40%) were treated at the community ED before the pediatric tertiary care center intervention and 435 (60%) were treated after the intervention. Treatment with steroids was significantly increased post intervention, with 76% of patients receiving steroids, compared with 60% of patients before the intervention.

©nata_zhekova/Thinkstock

[email protected]

Partnerships between community emergency departments and pediatric tertiary care centers are feasible and improve care of pediatric asthma, according to Theresa A. Walls, MD, of the Children’s National Health Systems, Washington, D.C., and her associates.

A total of 724 asthma patients aged 2-17 years were included in the study. Of this group, 289 (40%) were treated at the community ED before the pediatric tertiary care center intervention and 435 (60%) were treated after the intervention. Treatment with steroids was significantly increased post intervention, with 76% of patients receiving steroids, compared with 60% of patients before the intervention.

©nata_zhekova/Thinkstock

[email protected]

Partnerships between community emergency departments and pediatric tertiary care centers are feasible and improve care of pediatric asthma, according to Theresa A. Walls, MD, of the Children’s National Health Systems, Washington, D.C., and her associates.

A total of 724 asthma patients aged 2-17 years were included in the study. Of this group, 289 (40%) were treated at the community ED before the pediatric tertiary care center intervention and 435 (60%) were treated after the intervention. Treatment with steroids was significantly increased post intervention, with 76% of patients receiving steroids, compared with 60% of patients before the intervention.

©nata_zhekova/Thinkstock

[email protected]

The patient was given a diagnosis of vesicular (vesiculobullous) tinea pedis, based on the vesicles and bullae over the arch region of the foot. The arch is a typical location for vesiculobullous tinea pedis. There are 3 main types of tinea pedis: interdigital, moccasin distribution, and vesiculobullous (which is the least common type). Interdigital tinea pedis is the most common type and is typically seen between the fourth and fifth digits. The moccasin distribution tends to involve more erythema and scale—especially on the sides of the feet—giving the appearance of moccasins.

In general, tinea pedis is most commonly caused by Trichophyton rubrum. Other causative organisms include Trichophyton mentagrophytes and Epidermophyton floccosum. The vesiculobullous type of tinea pedis is usually caused by T mentagrophytes. The FP made this diagnosis clinically and did not perform a potassium hydroxide (KOH) preparation, as this type of tinea pedis has minimal scale and the dermatophyte may be harder to identify with the superficial scraping.

The FP prescribed 2 weeks of oral terbinafine 250 mg/d instead of relying on topical antifungal medicine because a better response can be expected with it. One month later, the vesiculobullous tinea pedis was fully resolved.

Photos and text for Photo Rounds Friday courtesy of Richard P. Usatine, MD. This case was adapted from: Usatine R, Reppa R. Tinea pedis. In: Usatine R, Smith M, Mayeaux EJ, et al, eds. Color Atlas of Family Medicine. 2nd ed. New York, NY: McGraw-Hill; 2013:799-804.

To learn more about the Color Atlas of Family Medicine, see: www.amazon.com/Color-Family-Medicine-Richard-Usatine/dp/0071769641/

You can now get the second edition of the Color Atlas of Family Medicine as an app by clicking on this link: usatinemedia.com

The patient was given a diagnosis of vesicular (vesiculobullous) tinea pedis, based on the vesicles and bullae over the arch region of the foot. The arch is a typical location for vesiculobullous tinea pedis. There are 3 main types of tinea pedis: interdigital, moccasin distribution, and vesiculobullous (which is the least common type). Interdigital tinea pedis is the most common type and is typically seen between the fourth and fifth digits. The moccasin distribution tends to involve more erythema and scale—especially on the sides of the feet—giving the appearance of moccasins.

In general, tinea pedis is most commonly caused by Trichophyton rubrum. Other causative organisms include Trichophyton mentagrophytes and Epidermophyton floccosum. The vesiculobullous type of tinea pedis is usually caused by T mentagrophytes. The FP made this diagnosis clinically and did not perform a potassium hydroxide (KOH) preparation, as this type of tinea pedis has minimal scale and the dermatophyte may be harder to identify with the superficial scraping.

The FP prescribed 2 weeks of oral terbinafine 250 mg/d instead of relying on topical antifungal medicine because a better response can be expected with it. One month later, the vesiculobullous tinea pedis was fully resolved.

Photos and text for Photo Rounds Friday courtesy of Richard P. Usatine, MD. This case was adapted from: Usatine R, Reppa R. Tinea pedis. In: Usatine R, Smith M, Mayeaux EJ, et al, eds. Color Atlas of Family Medicine. 2nd ed. New York, NY: McGraw-Hill; 2013:799-804.

To learn more about the Color Atlas of Family Medicine, see: www.amazon.com/Color-Family-Medicine-Richard-Usatine/dp/0071769641/

You can now get the second edition of the Color Atlas of Family Medicine as an app by clicking on this link: usatinemedia.com

The patient was given a diagnosis of vesicular (vesiculobullous) tinea pedis, based on the vesicles and bullae over the arch region of the foot. The arch is a typical location for vesiculobullous tinea pedis. There are 3 main types of tinea pedis: interdigital, moccasin distribution, and vesiculobullous (which is the least common type). Interdigital tinea pedis is the most common type and is typically seen between the fourth and fifth digits. The moccasin distribution tends to involve more erythema and scale—especially on the sides of the feet—giving the appearance of moccasins.

In general, tinea pedis is most commonly caused by Trichophyton rubrum. Other causative organisms include Trichophyton mentagrophytes and Epidermophyton floccosum. The vesiculobullous type of tinea pedis is usually caused by T mentagrophytes. The FP made this diagnosis clinically and did not perform a potassium hydroxide (KOH) preparation, as this type of tinea pedis has minimal scale and the dermatophyte may be harder to identify with the superficial scraping.

The FP prescribed 2 weeks of oral terbinafine 250 mg/d instead of relying on topical antifungal medicine because a better response can be expected with it. One month later, the vesiculobullous tinea pedis was fully resolved.

Photos and text for Photo Rounds Friday courtesy of Richard P. Usatine, MD. This case was adapted from: Usatine R, Reppa R. Tinea pedis. In: Usatine R, Smith M, Mayeaux EJ, et al, eds. Color Atlas of Family Medicine. 2nd ed. New York, NY: McGraw-Hill; 2013:799-804.

To learn more about the Color Atlas of Family Medicine, see: www.amazon.com/Color-Family-Medicine-Richard-Usatine/dp/0071769641/

You can now get the second edition of the Color Atlas of Family Medicine as an app by clicking on this link: usatinemedia.com